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Background: Imipenem/cilastatin is an antibacterial agent of the carbapenem class of β-lactams 
that is known to have an extremely wide spectrum of activity against Gram-positive, Gram-
negative, aerobic, anaerobic, and even multidrug-resistant strains. The objective of this study 
was to evaluate the appropriate use of imipenem/cilastatin in a local tertiary care hospital. The 
study assessed the indication both empirically and after the culture results were available, the 
dose and dose adjustment in renal failure, as well as the incidence of seizure in hospitalized 
patients receiving imipenem/cilastatin.
Methods: This observational study was conducted in a tertiary care hospital over a 3-month 
period. The treatment of 100 patients with imipenem/cilastatin was evaluated both empirically 
and after culture results were available. Analysis of the appropriateness of imipenem/cilastatin 
indication, dose, and monitoring of seizure frequency was based on the package insert, updated 
published guidelines, and clinical judgment.
Results: Patients from internal medicine and intensive care units comprised approximately 
50% of the population in the study. The patients received imipenem/cilastatin mainly for urinary 
tract infections (27%) or for sepsis of an unknown focus (22%). The use of imipenem/cilastatin 
empirically was appropriate in 97.2% (n=69/71) of the cases, and its use postculture in 86% of 
the cases. There were 29% of the patients who were not started on imipenem/cilastatin empiri-
cally. Four patients out of the 29 patients (13.8%) who were not started on imipenem/cilastatin 
empirically inappropriately received imipenem/cilastatin post-culture results. Thirty-three 
patients (33%) were not dosed appropriately, 30 of whom had renal impairment and creatinine 
clearance fluctuations. Only one patient developed a seizure while on imipenem/cilastatin.
Conclusion: The prescription of imipenem/cilastatin at our setting was mostly appropriate to 
what is recommended in the guidelines and the literature, although a few cases could have been 
managed better. Dosage adjustment, however, was not as appropriate, mainly in patients who 
did not have a stable creatinine clearance.
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Introduction
Antimicrobial resistance is recognized as one of the greatest threats to human 
health worldwide.1 Before the widespread use of antibiotics, there were low levels 
of pre-existing antibiotic-resistant bacteria.2 Evolutionary pressure requiring the 
recurrent use of antibiotics directly contributed to the development of multidrug-
resistant microorganisms and the spread of resistance among bacterial species.3 
The demand for the increased use of antibiotics as well as noncompliance with 
infectious disease guidelines both contribute to the rise of bacterial resistance.4 
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Seven decades of  medical advances enabled by antibiotics 
are now threatened by the rising antibiotic resistance and 
the withdrawal of most major pharmaceutical companies 
from the antibiotics market.5 Among infections caused by 
Gram-positive pathogens, methicillin-resistant Staphylo-
coccus aureus has taken center stage, now accounting for 
well over 50% of all documented staphylococcal infections 
in the US.6 In addition, Gram-negative bacteria, are also 
showing a decreased susceptibility to existing antibiot-
ics. Most alarming is the evolution of extended-spectrum 
β-lactamase-producing Enterobacteriaceae, as well as the 
multidrug-resistant Pseudomonas aeruginosa (some strains 
are even resistant to carbapenems). P. aeruginosa in the 
US is reported to have 20% resistance rates to imipenem/
cilastatin, a drug that is frequently utilized when a suspicion 
of an infection by that organism is high.7,8 Similarly, in 
Lebanon, the resistance rate of P. aeruginosa to imipenem 
is approximately 20%.9
Resistance rates have increased among several other 
Gram-negative pathogens that are often responsible for seri-
ous nosocomial infections, including Acinetobacter species 
and other Enterobacteriaceae.10 The presence of multidrug-
resistant strains of these organisms has been associated with 
very bad outcomes, including prolonged hospital stays, 
higher health care costs, and increased mortality, especially 
when the initial antibiotic therapy does not provide adequate 
coverage of the causative pathogen.10 In 2004, the Centers 
for Disease Control and Prevention reported an increasing 
number of multidrug-resistant Acinetobacter baumannii 
bloodstream infections.11
Multidrug-resistant strains of Acinetobacter species are 
being isolated with increasing frequency in many of the 
nosocomial infections, especially nosocomial pneumonia, 
bloodstream infections, surgical site infections, and uri-
nary tract infections.10 P. aeruginosa is also responsible 
for a wide range of severe nosocomial infections, includ-
ing pneumonia, urinary tract infections, and bacteremia.12 
In addition to its intrinsic resistance due to its rigid cell 
well, P. aeruginosa has also acquired resistance via mul-
tiple mechanisms, including production of β-lactamases 
and carbapenemases.13 Data from the National Nosocomial 
Infections Surveillance system in the US indicate that the 
incidence of nosocomial infections caused by Acinetobacter 
species and by P. aeruginosa increased drastically between 
1975 and 2003.14
Imipenem/cilastatin, the very first semisynthetic thien-
amycin, is an antibacterial agent of the carbapenem class of 
β-lactams that is known to have an extremely wide spectrum of 
antibacterial activity against Gram-positive, Gram-negative, 
aerobic, anaerobic, and even multidrug-resistant strains.15 It is 
active against a wide variety of aerobic and anaerobic bacteria 
that are resistant to other agents, including resistant strains 
of S. aureus, enterococci,  Enterobacteriaceae, P. aeruginosa, 
and Bacteroides fragilis.
Extensive clinical research marked the effectiveness of an 
initial monotherapy of imipenem/cilastatin in the treatment 
of moderate to severe infections, including nosocomial pneu-
monia, septicemia, febrile neutropenia, and intra-abdominal, 
diabetic foot, urinary tract, skin and soft tissue, as well as 
bone and joint infections.16 The dose of imipenem should be 
based on the location and severity of the infection, the sus-
ceptibility of the infecting pathogen(s), and the renal function 
of the patient. Adult patients with impaired renal function, as 
judged by creatinine clearance (CrCl) ,70 mL/min/1.73 m2, 
require dosage adjustment.
Many studies have addressed the  appropriateness of 
 imipenem/cilastatin prescription and dosing in health care 
institutions. Shiva et al,17 for instance, evaluated the utiliza-
tion of imipenem/cilastatin in an educational hospital in 
Iran and found that there was a high empirical prescription 
of imipenem/cilastatin without considering culture and anti-
microbial susceptibility results, and they found out that there 
was a lack of attention to dosage adjustments in patients with 
renal insufficiency. In another drug utilization evaluation 
conducted by Sakhaiyan et al,18 it was shown that dosage 
adjustment of imipenem/cilastatin was not being conducted 
appropriately at their institution, and the authors concluded 
that there was a need to further educate the health care pro-
fessionals since the adjustment is dependent on the weight 
and the renal function of the patient.
Seizure occurrence with the use of imipenem/cilas-
tatin has also been addressed extensively before. It was 
first reported by the manufacturer to be 0.4%. However, 
subsequent postmarketing surveys demonstrated that 
imipenem/cilastatin can be associated with seizures more 
frequently.19–21 Calandra et al22 reviewed 1,754 patients 
treated with  imipenem/cilastatin to determine the seizure 
risk associated with carbapenems. Patients were moderately 
to severely ill, with numerous risk factors for seizures. 
Seizures occurred in 3% of patients, but only 0.9% of 
them were judged to be possibly, probably, or definitely 
related to imipenem/cilastatin. As with other β-lactam 
antibiotics, central nervous system (CNS) disorders and 
renal insufficiency were risk factors for seizure occur-
rence. The patients who received imipenem/cilastatin at 
higher than recommended doses had an increased risk of 
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seizures, especially the subgroup of patients with renal 
insufficiency.22
The objective of this study is to evaluate the appropriate-
ness of imipenem/cilastatin prescription and dosing in a local 
tertiary care hospital. The study assesses the indication both 
empirically and after the culture results are available, the dose 
and the dose adjustment in renal failure, as well as the occur-
rence of seizures in patients on imipenem/cilastatin.
Methods
setting and design
This study was designed to be of a prospective, observational 
nature. However, in order to have an acceptable sample size 
(n=100 patients), a retrospective patient evaluation was 
also included. This observational study was conducted in a 
tertiary 544-bed teaching hospital over a 3-month period. 
Information on 100 patients receiving imipenem/cilastatin 
for treatment of infections in all hospital units was collected 
using a data collection form that included the following: 
demographic data, allergy history, past medical history, 
history of present illness, history of CNS diseases and/or 
seizure, site(s) of infection, imipenem/cilastatin dosage, 
frequency of administration, bacterial culture(s) and sensitiv-
ity results, temperature, white blood cell count, neutrophil 
count, serum creatinine, and calculated CrCl according to 
the Cockcroft–Gault equation in adults and the Schwartz 
equation in pediatrics. A few patients did not have their 
weights documented, so their weight was estimated and then 
used in the calculation of their estimated CrCl. Electronic 
medical charts/records on all patients receiving imipenem/
cilastatin were also reviewed. The study was approved by 
the  Institutional Review Board, and a waiver of consent was 
obtained to fill out the data collection form.
Imipenem/cilastatin treatment was evaluated both 
empirically and after the culture results were out. The analysis 
included the data collected from the initiation of the first dose 
of imipenem/cilastatin until patient discharge and/or discon-
tinuation of the antibiotic. Analysis of the appropriateness of 
the use of imipenem/cilastatin was evaluated based on the 
Infectious Diseases Society of America guidelines,23–27 the 
Surviving Sepsis Campaign guidelines,28 drug information 
handbook dosage recommendations,29–31 and clinical judg-
ment. The data collection form and final project report did 
not include any subject identifiers.
After obtaining the culture results, imipenem/cilastatin 
was considered to be appropriate if it was the only antibiotic to 
which the microorganism was sensitive to and if de- escalation 
to a narrower spectrum antibiotic was not possible.
sources of data
An electronic daily list of all patients prescribed imipenem/
cilastatin was provided by the central pharmacy. Patients who 
received imipenem/cilastatin for treatment were then identified 
using the hospital’s computerized chart system. Indication, 
dose, and clinical improvement or worsening of the symptoms 
of patients receiving imipenem/cilastatin were followed until 
discontinuation of the antibiotic.  Bacterial cultures were also 
followed up throughout the duration of the treatment.
statistical analysis
Data were processed and analyzed through the application of 
the software Statistical Package for Social Sciences (SPSS, 
version 19, IBM Corporation, Armonk, NY). Responses 
were tabulated and cross-tabulated, and percentages were 
calculated.
Results
Patient distribution
Over the 3-month period of the study, the electronic medical 
charts/records of 100 patients receiving imipenem/cilastatin 
were reviewed. The study patients were distributed over many 
hospital units, with the largest proportions from internal 
medicine (28%) and intensive care (21%) units. The others 
were  distributed over the surgery (16%),  oncology (13%), 
pediatrics (12%), and cardiac care (10%) units (Table 1).
Table 1 Demographic and clinical characteristics of the patients 
(n=100)
sex
 Male 59 (59%)
 Female 41 (41%)
agea (years) 54.9±25.6
Diagnosis
 Urinary tract infection 27 (27%)
 sepsis (unknown focus) 22 (22%)
 nosocomial pneumonia 19 (19%)
 Febrile neutropenia 10 (10%)
 Unknown focus 9 (9%)
 skin and soft tissue infection 4 (4%)
 Diabetic foot infection 2 (2%)
 Intra-abdominal infection 2 (2%)
 Bone and joint infection 2 (2%)
 Others 3 (3%)
Wards
 Internal medicine 28 (28%)
 Intensive care unit 21 (21%)
 surgery 16 (16%)
 Oncology 13 (13%)
 Pediatrics 12 (12%)
 cardiac care unit 10 (10%)
Notes: aValues are presented as mean ± standard deviation. Median: 61.5 years; 
interquartile range: 33.7 years.
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A summary of the demographics of the patients in 
this study is shown in Table 1. The majority of patients 
on  imipenem/cilastatin were males (59%). The age of the 
patients ranged from 1 day to 90 years with a standard 
deviation of 25.6 years. The patients’ baseline estimated 
CrCl ranged from 9 mL/min to 255 mL/min with a standard 
deviation of 83.61 mL/min. The standard deviation values 
are considerably high for both the age and the CrCl of the 
patients, which proves the wide variability of those two par-
ticular data sets among patients.
According to the guidelines, the patients were classified 
in groups according to their CrCl. The average CrCl was 
calculated for every patient while at the hospital, according 
to the  Cockcroft–Gault equation, and every patient had their 
serum creatinine regularly monitored for any requirement 
of dose adjustment, including hemodialysis patients. Forty-
nine percent (49%) of the patients had a CrCl $70 mL/min 
and required no dosage adjustment. The remaining patients 
(51%) needed to have the imipenem/cilastatin dose adjusted 
accordingly (Table 2).
Indication
Extensive clinical research marked the effectiveness of an 
initial monotherapy of imipenem/cilastatin in the treatment 
of moderate to severe infections, including septicemia, 
neutropenic fever, and intra-abdominal, lower respiratory 
tract, genitourinary, gynecological, skin and soft tissue, and 
bone and joint infections.16 The majority of the patients were 
diagnosed with urinary tract infections (27%) typically due 
to an extended-spectrum β-lactamase-producing organism 
or sepsis of an unknown focus (22%). The indication for the 
use of imipenem/cilastatin in the 100 patients is in Table 1. 
Nosocomial pneumonia was the indication in 19% and febrile 
neutropenia in 10% of the patients. Intra-abdominal, bone 
and joint, and diabetic foot infections were the least common, 
each accounting for only 2% of the patients.
The use of imipenem/cilastatin empirically was 
appropriate for the indication in 97.2% (n=69/71) of the 
cases. Two patients out of 71 (2.8%) had been inappropriately 
prescribed imipenem/cilastatin empirically.
As for the assessment of imipenem/cilastatin indication 
postculture results, 11% of the patients were inappropriately 
started on and/or inappropriately continued imipenem/cilas-
tatin after the culture results (Table 3).
Of the patients who were started on imipenem/cilastatin 
empirically, 78.8% (n=56/71) continued this treatment after 
the culture results. Seven of these patients (12.5%, n=7/56) 
were inappropriately kept on imipenem/cilastatin. Three 
patients (5.3%, n=3/56) of those who were started on the 
antibiotic empirically did not have culture results taken 
(Table 3).
Twenty-nine percent of the patients were not started 
on imipenem/cilastatin empirically, four of whom (13.7%, 
n=4/29) inappropriately received imipenem/ cilastatin post-
culture results (Table 3).
Dose
Forty-nine percent of the patients had no (and did not 
develop) renal impairment (CrCl ,70 mL/min) (Table 4). 
Fifty-one patients (51%) either already had baseline renal 
impairment or had worsened kidney function while at the 
hospital (CrCl ,70 mL/min). Out of the 49 patients who 
did not have renal impairment, only three (6.1%) were 
dosed inappropriately. As for the rest of the patients (those 
with CrCl ,70 mL/min), 58.8% (n=30/51) were not given 
an appropriate dose. In total (irrespective of the patients’ 
renal function), 33 patients out of 100 were not dosed 
appropriately (Table 4).
Monitoring of seizure occurrence
Out of all the patients included in this study, only one 
patient developed a seizure. The patient presenting with 
nosocomial aspiration pneumonia was started on imi-
penem/cilastatin empirically after obtaining a sputum 
sample for culture. The culture result revealed the pres-
ence of Escherichia coli (extended-spectrum β-lactamase 
producer) in her sputum, and imipenem/cilastatin was 
continued based on her postculture results. She did not 
have renal impairment and her CrCl was stable (.100 
mL/min) at all times. But it is important to note that she 
had a history of pre-existing CNS disease, evident by an 
old magnetic resonance image. Because of the seizure this 
patient developed, imipenem/cilastatin was discontinued 
and replaced by colistin (polymixin E) after consulting the 
infectious diseases team.
Table 2 estimated baseline creatinine clearance for patients 
started on imipenem/cilastatin
Estimated baseline creatinine  
clearancea (mL/min)
Number of 
patients 
$70 49 (49%)
41–69 11 (11%)
21–40 24 (24%)
6–20 16 (16%)
Notes: aMedian: 74.5 ml/min; interquartile range: 128 ml/min; sample size n=100.
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Discussion
This is the first study conducted at this hospital that evalu-
ates the appropriateness of imipenem/cilastatin prescription 
empirically, its dosage (and dosing adjustment whenever 
required) before and after culture results, and the rate of 
occurrence of seizures in the study patients.
Based on the results of this study, imipenem/cilastatin 
was appropriately used in 97% of the cases when it was 
prescribed empirically. A similar study that assessed 
the empirical use of imipenem/cilastatin conducted in 
a university hospital in Chile showed a lower rate of 
appropriateness as compared to our study.32 In that study, 
58.1% (n=79/136) of empirical imipenem/cilastatin use 
was considered to be appropriate, while 11.8% was not 
appropriate (n=16/136). The remaining patients either 
discontinued imipenem/cilastatin by physicians in charge 
prior to evaluation (20.6% n=28/136) or, unfortunately, 
died (9.6% n=13/136).32 In another study, by Sakhaiyan 
et al,18 which also assessed the appropriateness of the use of 
imipenem/cilastatin empirically but in patients undergoing 
bone marrow transplantation at a single hospital and at a 
specific ward, 22 patients (35.9%) needed dosage adjust-
ments due to low weight or renal failure, but no action was 
taken at the time. Moreover, a study conducted in Iran by 
Shiva et al17 also addressed the same topic, and the authors 
came to the conclusion that the dosage of imipenem was 
inappropriate in 36% of patients, and the dosage adjustment 
(when needed) was either not done or done inappropriately 
in 64.3% (n=9/14) of patients.
The high percentage of appropriateness in imipenem/
cilastatin prescription at our setting was due to the fact that the 
physicians were compliant with the current guidelines and, 
most importantly, due to the implementation of a restriction 
policy at the hospital that allows the infectious diseases team 
to reject or authorize, within 24 hours, the use of imipenem/
cilastatin after an evaluation of its appropriateness for use.
When the use of imipenem/cilastatin based on postculture 
results was assessed, the degree of appropriateness decreased 
at our institution to 86%, and that was after including patients 
who had been started on imipenem/cilastatin after the culture 
results were available. This was mainly due to the multiple 
chances of de-escalation that did not occur when possible. 
In addition, some patients were started on other antibiotics 
but kept on imipenem/cilastatin despite evidence that the 
microorganism identified turned out to be resistant to imi-
penem/cilastatin. In a few cases when imipenem/cilastatin 
was started after the culture results were out, four patients 
out of 29 (13.8%) were inappropriately started on imipenem/
cilastatin. These patients either could have been placed on an 
antibiotic of a narrower spectrum (n=1) or should not have 
been placed on imipenem/cilastatin in the first place, due to 
the resistance of the identified microorganism to the drug 
(n=3). Thus, the appropriateness of use of imipenem/cilas-
tatin with respect to indications at our hospital is relatively 
acceptable but could be further improved.
The dosing of imipenem/cilastatin assessed in this study 
was shown to be appropriate in only 67% of the cases. It 
is important to highlight the fact that the inappropriate-
ness in the dosing regimen among the rest of the patients 
(33%) was mainly evident in patients who already had a 
low CrCl (,70 mL/min) or those who had developed renal 
impairment while at the hospital. In total, three patients 
without baseline renal impairment and 30 patients with 
baseline renal impairment received an inappropriate dose 
of imipenem/cilastatin.
When there was no focus of infection, the dose of imipenem/
cilastatin prescribed was the average recommended dose in 
the references.
Guidelines are present for appropriate dosing of  imipenem/
cilastatin in renal dysfunction, taking into account body weight, 
infecting pathogen, and CrCl.33 It is important to note that a con-
siderable number of patients did not have their weight recorded 
Table 3 appropriateness of imipenem/cilastatin use postculture
Time of starting Number of patients (n) Appropriate Inappropriate Culture not taken
empirically (71) continued 
Discontinued
56 (78.8%) 
15 (21.1%)
46 (82.1%) 
15 (100%)
7 (12.5%) 
0
3 (5.3%) 
0
nonempirically (29) started 29 25 (86.2%) 4 (13.7%) 0
Total 100 86 (86%) 11 (11%) 3 (3%)
Table 4 appropriateness of the dose of imipenem/cilastatin
Renal status Number  
of patients (n)
Appropriate Inappropriate
crcl $70 ml/min 
crcl ,70 ml/min
49 
51
46 (93.9%) 
21 (41.2%)
3 (6.1%) 
30 (58.8%)
Total 100 67 (67%) 33 (33%)
Abbreviation: crcl, creatinine clearance.
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on the electronic chart, thereby mandating the estimation of 
their weight.
The most widely used empirical dose of imipenem/
cilastatin was 500 mg given intravenously four times daily, 
sometimes regardless of the patient’s weight. This was one 
of the most documented causes of inappropriate initial 
dosing of imipenem/cilastatin. Another reason was that, in 
several cases, doses were not adjusted according to varying 
serum creatinine levels (whether improving or worsening). 
Guidelines emphasize the importance of periodic assess-
ment of renal function and adjusting the dose  accordingly.34 
 Frequent monitoring of the renal function of patients receiv-
ing imipenem/cilastatin is necessary. Patients with a CrCl of 
,70 mL/min require more intensive follow-up to adjust their 
dose of imipenem/cilastatin when needed.
This study also evaluated the propensity of seizures with 
the use of imipenem/cilastatin. Out of the 100 patients, only 
one female patient developed a seizure, which was myoclonic 
in nature and was associated with movement of the hands 
and deterioration of consciousness. She did not have renal 
impairment and her CrCl was stable (.100 mL/min) at all 
times. Many clinical trials have assessed the rate of seizure 
occurrence in patients receiving imipenem/cilastatin, and 
patients who were at the highest risk of seizures were those 
who had a pre-existing CNS disease and/or a seizure history, 
those who were receiving higher than recommended doses, 
and those patients with renal insufficiency. The patient who 
developed a seizure was receiving 500 mg intravenously four 
times daily, which was the appropriate dose for her. However, 
the patient had a history of pre-existing CNS disease, which 
increased her risk of developing a seizure while on imipenem/
cilastatin. This patient had several comorbidities alongside 
the nosocomial aspiration pneumonia, which made it diffi-
cult for us to establish a causal relationship with imipenem/
cilastatin.16 However, none of the other patients, including 
the 15 other patients (15%) who also had pre-existing CNS 
disease and/or a history of seizure, developed any kind of 
seizure activity.
Appropriate imipenem/cilastatin prescribing, dosing, and 
monitoring proved to be of great impact on morbidity and 
mortality of hospitalized patients. In a study  conducted by 
Thuong et al, it was found that only 75% of the  empirical 
prescribing of antibiotics was later supported by culture 
results.35 Therefore, it is especially important that therapy 
be re-evaluated and, if necessary, modified 3–4 days after 
initiation of therapy and after culture results are available. 
The presence of a clinical pharmacist would help address the 
appropriateness in initial empirical prescription and then the 
re-evaluation of therapy after culture results are available, in a 
way that is compliant with the guidelines. Moreover, a study 
has shown that hospitals that have restricted carbapenem 
regulations use significantly fewer carbapenems (P=0.04) 
and report significantly lower incidence rates of carbapenem-
resistant P. aeruginosa for up to 5 years (P=0.01).36 Another 
study also concluded that carbapenem constraint could 
reduce the incidence of multidrug-resistant A. baumannii in 
ventilator-associated pneumonia (P,0.05).37
There are several limitations to this study. First, it is an 
observational study; therefore, the cause–effect relationship 
between elements could not be ensured. Second, the observa-
tional period was relatively short, which led to a limited num-
ber of patients. Third, the study took place in one academic 
tertiary care center, which limits the ability to generalize the 
results. Fourth, keeping in mind that the Cockcroft–Gault 
method was used to provide a CrCl estimate and it requires 
information about age, sex, serum creatinine, and weight, 
some of the patients’ body weights were estimated when they 
were not documented in the patients’ records. Additionally, 
using the estimated CrCl equations for patients with acute 
kidney injury made the results difficult to interpret. Ideally, 
urine creatinine collection should be employed.
Conclusion
In general, this study evaluates prescribing patterns at our 
hospital and evaluates the compliance to national guidelines. 
The prescription of imipenem/cilastatin per indication at our 
hospital was mostly appropriate to what is recommended 
in the guidelines, although a few cases could have been 
managed better.  Dosage adjustment, however, was not as 
appropriate, mainly in patients who did not have a stable 
CrCl. The need for interventional actions by a clinical 
pharmacist on imipenem/cilastatin use is essential in the 
various units of the hospital. A clinical pharmacist may be 
able to help regulate the use of imipenem/cilastatin, ensure 
appropriate dosage adjustment when necessary, educate 
other health care professionals, improve patient outcomes, 
and decrease the length of hospital stay.38 In conclusion, the 
implementation of the restriction policy at our institution is 
the reason why the prescription of imipenem/cilastatin was 
close to ideal. However, to improve the dosage adjustment of 
 imipenem/cilastatin, gathering of recorded data about inap-
propriate therapy should be provided to the physicians to be 
able to evaluate and optimize future drug therapies. In addi-
tion, further involvement of a clinical pharmacist in each 
hospital ward can lead to timely patient follow-up and the 
adjustment of imipenem/cilastatin dose when required.
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